Celgene reports 2012 earnings, affirms 2013 guidance

Celgene Corp. (NASDAQ:CELG) reported 4Q12 adjusted diluted EPS of $1.32, beating by a penny the Street's estimate of $1.31 and up 26% from $1.05 in 4Q11. Revenues for the quarter rose 13% to $1.45 billion, coming in just below the Street's estimate of $1.46 billion. For the year, Celgene reported adjusted diluted EPS of $4.91, up 30% from $3.79 in 2011. The Street was expecting $4.89. Revenues increased 14% to $5.51 billion from $4.84 billion in 2011, but came in just shy of the Street's $5.52 billion estimate. Sales of Revlimid lenalidomide for multiple myeloma (MM) and myelodysplastic syndromes (MDS) were $1 billion in the quarter and $3.8 billion for the year, both up 17% from the respective periods in 2011. Additionally, Celgene said it repurchased about $580 million in shares during 4Q12, with about $1.8 billion remaining under its stock repurchase program. ...